Unknown

Dataset Information

0

Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up.


ABSTRACT: Purpose:The purpose of the study was to assess the efficacy of intravitreal dexamethasone implant (IDI: Ozurdex®) injection in eyes with macular edema due to retinal vein occlusion. Material and Method. A retrospective, nonrandomized study was conducted in patients with macular edema (ME) due to retinal vein occlusion (RVO) who undertook intravitreal Ozurdex® as first-line treatment. We performed a complete ocular exam including macular OCT. Results:The mean BCVA (logMar) improved from 0.420.42?±?0.23 logMar at baseline to 0.21?±?0.23 logMar at 48 weeks in the BRVO group and from 0.72?±?0.16 logMar at baseline to 0.31?±?0.23 logMar at 48 weeks in the CRVO group. In both groups, CFT values decreased significantly compared to baseline (p < 0.0001 at each timepoint). Reinjection for recurrent macular edema after 18 weeks was indicated in five eyes (41.67%) in the BRVO group and in six eyes (25%) in the CRVO group. Cataract developed in two eyes (16.67%) in the BRVO group and in one eye (4.17%) in the CRVO group. The IOP was higher than 25?mmHg in two cases in the BRVO group (16.66%) and in three cases (8.33%) in the CRVO group. Conclusion:Ozurdex® injected intravitreally significantly improved the mean CFT and BCVA in eyes with macular edema due to retinal vein occlusion.

SUBMITTER: Nicula C 

PROVIDER: S-EPMC7036098 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5488787 | BioStudies
1000-01-01 | S-EPMC5554567 | BioStudies
2019-01-01 | S-EPMC6440600 | BioStudies
2017-01-01 | S-EPMC5241684 | BioStudies
2019-01-01 | S-EPMC6588881 | BioStudies
2016-01-01 | S-EPMC5019367 | BioStudies
2017-01-01 | S-EPMC5598918 | BioStudies
2019-01-01 | S-EPMC6832619 | BioStudies
2015-01-01 | S-EPMC6600806 | BioStudies
2011-01-01 | S-EPMC3169220 | BioStudies